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This is the first report to correlate DARPP-32 immunoreactivity (dopamine and cAMP-regulated phosphoprotein, Mr 32000) to
clinicopathological status in human cancer. DARPP-32 is recognised as a neuronal protein. A recent study demonstrated that DARPP-
32, and a truncated isoform t-DARPP, are overexpressed in gastric carcinoma during the process of carcinogenesis. The biological
function of DARPP-32, however, is still unclear. The purpose of this study was to clarify the roles of DARPP-32 and t-DARPP in
oesophageal squamous cell carcinoma (OSCC). Initially, we investigated DARPP-32 and t-DARPP expression in OSCC cell lines by
Reverse transcription–polymerase chain reaction and Western blot. DARPP-32 expression was observed in four out of seven
(57.1%) cell lines, but t-DARPP expression was not observed in any cell lines. In oesophageal tissue sample, DARPP-32 expression
was observed in four out of seven (57.1%) tumour tissues, while t-DARPP was not observed in any tissues. Subsequently, DARPP
expression was assessed by immunohistochemistry, using a polyclonal antibody, in tissue sections from 122 patients with primary
OSCC. DARPP immunoreactivity was not observed in any normal oesophageal mucous membranes. On the other hand, positive
DARPP immunostaining was detected in 37 patients (30.3%) and correlated inversely with pathologic stage (P¼0.0284), pT
(P¼0.0438), pN (P¼0.0303) and tumour size (P¼0.012). The overall survival rate was worse in patients with DARPP-negative
tumours than in patients with DARPP-positive tumours (P¼0.0453). Interestingly, DARPP expression was observed in only one out
of 45 cases of dysplasia. These observations suggest that DARPP-32 (rather than t-DARPP) expression arises after a phase of
dysplasia in OSCC, and that tumours expressing DARPP-32 progress less rapidly than DARPP-32-negative tumours.
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Oesophageal carcinoma remains a disease with poor prognosis.
Advances in surgical technique and perioperative management
have improved survival to some extent. The overall 5-year survival
rate, however, generally remains less than 50%, even with the use
of multimodality therapy (Ando et al, 1997, 2000; Collard et al,
2001). This is despite a better understanding of the molecular basis
of oesophageal carcinogenesis and identification of prognostically
important biologic markers.
DARPP-32 (dopamine and cAMP-regulated phosphoprotein, Mr
32000) is recognised as a neuronal protein. In brain, DARPP-32 is
a potent inhibitor of a cell cycle regulatory enzyme, protein
phosphatase-1 (PP1) (Bibb et al 1999; Greengard, 2001), and can
mediate phosphorylation and activation of mitogen-activated
protein kinase (MAPK) and c-AMP-responsive element-binding
protein (CREB), an inhibitor of apotosis (Yan et al, 1999).
Furthermore, DARPP-32 orchestrates the degree of phosphoryla-
tion in a variety of molecular targets in the cell membrane and
cytoplasm (Greengard, 2001). DARPP-32 and t-DARPP have been
proposed to be factors providing an important survival advantage
to neoplastic cells and may be important for gastric tumorigenesis
(Wa’el et al, 2002). However, thus far, little is known about the role
of DARPPs in carcinogenesis. Here, we examined DARPP-32 and t-
DARPP expression and immunoreactivity in OSCC cell lines in
archival material obtained from 122 surgical specimens of
oesophageal squamous cell carcinoma (OSCC) with clinical and
histopathologic factors obtained by a retrospective review of
patient records.
MATERIALS AND METHODS
Cell lines and culture conditions
Human OSCC cell lines TE2, TE5, TE8, TE10 and TE13 were
generously provided by Dr Nishihira (University of Tohoku,
Japan). HEC46 was provided by Dr Toge (University of Hiroshima,
Japan), and SGF7 was provided by Dr Saito (Toyama Medical and
Pharmaceutical University, Japan). TE2, TE5, TE8, TE10, TE13 and
HEC46 cells were grown in Dulbecco’s modified Eagle’s medium
(D-MEM, Sigma-Aldrich Co., Ltd., Irvine, CA, USA) with 10% fetal
bovine serum (FBS), and 1% penicillin/streptomycin (p/s). SGF7
cells were maintained in RPMI-1640 medium (Sigma-Aldrich Co.,
Ltd.) with 10% FBS and 1% p/s. All cell lines were maintained in a
humidified incubator with 5% CO2 in air at 371C.
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Tumour and normal tissue samples were snap-frozen and stored at
 801C. The samples were obtained in 2002 from resections
directly after surgery. Frozen sections (5mm) were stained with
haematoxylin and eosin (H & E) to verify OSCC and approximately
0.1g of the tumour block was processed for RNA extraction
using the TRIZOL Reagent (GIBCO BRL, Grand Island, NE,
USA).
Reverse transcriptase–polymerase chain reaction (RT–
PCR)
Total cellular RNA was isolated with TRIZOL Reagent (GIBCO
BRL) from each cell line. Each 20ml cDNA synthesis reaction
contained 1mg of total RNA, 1  First Strand Buffer (GIBCO BRL);
50mM Tris-HCL, pH 8.3, 75mM KCL, 3mM MgCl2), 0.5mM of each
deoxynucleotide triphosphate, 200U of SUPERSCRIPT II (GIBCO
BRL), 10mM dithiothreitol and 0.5mg oligo (dT) (GIBCO BRL).
The reverse transcription (RT) reaction was carried out for 50min
at 421C and inactivated by heating at 701C for 15min. Multiplex
PCR was performed as described previously (Wong et al, 1994).
Briefly, each 25ml reaction contained 2ml of RT reaction products,
1U of Taq DNA polymerase (Boehringer Mannheim, Germany),
1  PCR buffer (Boehringer Mannheim), 160mM of each
deoxynucleotide and 20pmol of each 30 and 50 primer specific
for DARPP-32 (sense, 50-gaagatccagttctcgg-30; antisense 50-ACT-
TAGTGCTGGGTCTTCC-30), t-DARPP (sense, 50-gttccggctctcagag-
ca-30; antisense 50-ACTTAGTGCTGGGTCTTCC-30), and b-actin
(sense, 50-AATCGTGCGTGACATTTAG-30; antisense 50-
GTCCACGTCACACTTCATG-30). DARPP-32, t-DARPP and b-actin
cDNA were amplified for 30 cycles. Conditions for DARPP-32 PCR
were 941C for 30s, 521C for 30s, then 721C for 30s. Conditions for
t-DARPP PCR were 941C for 30s, 531C for 30s, then 721C for 30s.
Conditions for b-actin PCR were 941C for 30s, 511C for 30s,
then 721C for 30s. All PCR products were electrophoresed in a
2.0% agarose gel and visualised by ethidium bromide staining.
As positive controls, plasmids expressing DARPP-32 or t-DARPP
were generated by PCR amplification of the full-length
cDNA derived from gastric cancer tissue and cloning into the
BamHI and HindIII sites of pCEP4 (Invitrogen Corp., Carlsbad,
CA, USA).
Western blot
Western blot analysis was performed to analyse DARPP-32 and t-
DARPP expression in oesophageal cancer cell lines. Cell lysates
were prepared in SDS buffer containing 62.5mM Tris-HCl pH6.8,
2% wv
 1 SDS, 10% glycerol, 50mM DTT, 0.1% wv
 1 bromphenol
blue, 1mM PMSF. Total proteins (40mg: OSCC cell lines, 2mg:
tranfected cell lines) were electrophoresed in 15% SDS–poly-
acrylamide gels and transferred onto nitrocellulose membranes.
Rabbit anti-DARPP polyclonal antibody (H-62; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) was used as the primary
antibody (1:1000). Peroxidase-conjugated goat F(ab’)2 anti-rabbit
IgG (Jackson ImmunoReserch, West Grove, PA, USA) was used as
the secondary antibody (1:5000). Detection of bound antibodies
was performed using the ECL system (Amersham, Aylesbury, UK).
The plasmids expressing DARPP-32 or t-DARPP were transfected
into TE8 cells using Lipofectamine (Invitrogen Corp.) and these
lysates were used as positive controls.
Patients and oesophageal specimens
All complete OSCC surgical specimens resected from 1989 to 1999,
from patients with no evidence of metastasis to other organs and
without prior anticancer treatment, were examined. Cases of in-
hospital death were excluded. Surgical specimens from 122
patients who had undergone radical oesophagectomy at the
Department of Surgical Oncology, Hokkaido University, Hokkaido
Gastroenterology Hospital, and Teine Keijinkai Hospital were
included in the current study, and findings were referred to the
patients’ clinical records. One of the sections from the deepest
point of each tumour invasion was selected for evaluation. The
specimens were examined histologically after staining with H & E,
and the clinicopathologic stage was determined according to the
TNM classification system of the International Union Against
Cancer (Sobin and Wittekind, 2002). Specimens from 122 patients
were included in the current study (105 males and 17 females). The
median patient age was 62.3 years (range, 38–82 years). A
relatively large number of patients had early-stage disease (78
patients, 63.9%). In total, 61 patients (50.0%) had lymph node
metastases and 19 patients (16%) had distant nodal metastases.
The study population had the following performance status (PS):
PS0, 107 patients; PS1, 14 patients; and PS2, one patient. The
median follow-up period was 29 months.
All specimens were fixed in 10% formalin and embedded in
paraffin wax. One of the deepest sections from each tumour was
selected for evaluation, and serial 4mm-thick sections were
examined by immunohistochemistry.
Immunohistochemistry
Unstained sections were treated with a rabbit anti-DARPP
polyclonal antibody (H-62; Santa Cruz Biotechnology; 1:200
dilution), using previously described conditions (Oliver and
Shenolikar, 1998). Briefly, each slide was deparaffinised by routine
techniques, treated with sodium citrate buffer (Ventana-Bio Tek
Solutions, Tucson, AZ, USA), and then treated with microwave
heat for 20min. After cooling for 5min, slides were labeled with
antibody using the Ventana EX system automated stainer
(Ventana-Bio Tek Solutions). The anti-DARPP-32 antibody was
detected by adding biotinylated secondary antibody, avidin–biotin
complex and 3, 30-diaminobenzene (Ventana DAB Universal Kit;
Ventana-Bio Tek Solutions). Sections were then counterstained in
haematoxylin for 1min and mounted in Permount (Microslides;
Muto-Glass, Tokyo, Japan). For a negative control, nonimmune
purified rabbit serum was used for the primary antibody. The
number of stained cells per 1000 was determined under a
microscope (Olympus Optical Co., Ltd, Tokyo, Japan) in three
visual fields, at a magnification  200. When microscopic
examination indicated that a the total number of cancer cells
observed being less than 1000, all cells were counted. When over
10% cancer cell nuclei and cytoplasm were stained, the tumour was
considered DARPP-32 positive. The current study was performed
in a retrospective manner, while all specimens were evaluated by
three investigators (YE, MM and TI), who were blinded to the
patients’ clinical information. Dysplasia was defined according to
the WHO classification (Stanley and Lauri, 2000).
Statistical analysis
Either the w
2 test or Fisher’s exact test were used to analyse the
correlation between DARPP-32 expression and patients’ para-
meters, including histopathologic findings. The Kaplan–Meier
method was used to generate survival curves, and survival
differences were analysed with the log-rank test, based on the
status of DARPP-32 expression. Univariate and multivariate
analyses of DARPP immunoreactivity and clinicopathological
features were performed using the Cox proportional hazard
regression model. Probability values of less than 0.05 were
regarded as indicating significance. All analyses were performed
using statistical analysis software (Statview J version 5.0; SAS
Institute Inc., Cary, NC, USA).
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Expression of DARPPs in OSCC cell lines
DARPP-32 RT–PCR fragments were amplified from four out of
seven cell lines, while t-DARPP fragments were not amplified in
any cell lines (Figure 1A). Western blot analysis showed that a
32kDa protein, corresponding to DARPP-32, was expressed
strongly in TE2 and TE13, while t-DARPP protein (30kDa) was
not detectable in any cell lines, as expected based on the RT–PCR
data (Figure 1B).
Detection of DARPPs in human tissues
In oesophageal sample tissues, DARPP-32 RT–PCR fragments
were amplified from four out of seven tumour tissues, but not from
any normal oesophageal mucosa. As in the cell lines, t-DARPP
RT–PCR fragments were not amplified from any sample tissues
(Figure 2).
Immunohistochemical analysis
We subsequently performed immunohistochemical analysis on the
122 OSCC specimens. This analysis provides suggestions as to the
biological function of DARPP in OSCC. DARPP immunoreactivity
was observed at the cancer cell membrane and cytoplasm, as seen
in a previous study (Wa’el et al, 2002). DARPP was expressed in
normal oesophageal gland cells (Figure 3A) and gangliocytes
(Figure 3B), permitting their use as a positive internal control. No
DARPP expression was detected in normal oesophageal mucous
membrane (Figure 3C). In tumour cells, immunoreactivity was
observed very vividly (Figure 3D), with 37 patients (30.3%)
staining positive for DARPP and 85 patients (69.7%) staining
negative (Figure 3E).
Dysplasias were found in 45 of 122 specimens, but DARPP
expression was only observed in one of theses lesions. A total of 36
patients with DARPP-positive tumours had DARPP-negative
dysplasias (Figure 3F).
Statistical analyses between DARRP expression and
clinicopathological data
DARPP immunoreactivity had an inverse relationship with
pathologic stage, pT, pN and tumour size by the w
2 test (Table 1).
Moreover, overall survival rate by the Kaplan–Meier method was
worse in patients with DARPP-32-negative tumours than in
patients with DARPP-32-positive tumours (Figure 4). Upon
univariate analysis with Cox proportional hazards model, DARPP
immunopositivity was inversely correlated with poor prognosis,
although, multivariate analyses did not indicate that DARPP
positivity was significant (data not shown).
DISCUSSION
DARPPs are frequently expressed in gastric cancer. To assess the
biological significance, we screened for DARPP expression in
TE2 TE5 TE8 TE10 TE13 HEC46SGF7 P.C.
t-DARPP
DARPP-32
DARPP-32 t-DARPP
TE8
A
B
-actin
32 kDa
30 kDa
TE2 TE5 TE8 TE10 TE13 HEC46 SGF7
-actin
Figure 1 RT–PCR expression analyses. (A) A gel imaging for DARPP-
32, t-DARPP and b-actin expression at 30 cycles by RT–PCR. Seven
oesophageal squamous cell lines, and positive controls (pCEP4-DARPP-32,
pCEP4-t-DARPP) are shown. (B) DARPP protein expression. Seven
oesophageal squamous cell lines and TE8 cells transfected with pCEP4-
DARPP and pCEP4-t-DARPP were separated by SDS–PAGE and analysed
for DARPP protein expression by Western blot with a COOH-terminal
DARPP-32 antibody (Santa Cruz Biotechnology).
N Ca N Ca N Ca N Ca N Ca N Ca Ca N
t-DARPP
DARPP-32
-actin
1 2 3 4 5 6 7 P.C.
Figure 2 RT–PCR expression analyses. A gel imaging for DARPP-32, t-
DARPP and b-actin expression at 30 cycles by RT–PCR. Seven different
samples of normal oesophageal mucosa (N), tumour tissues (Ca) and
positive control (pCEP4-DARPP-32, pCEP4-t-DARPP) are shown.
A
B
C
D
E
F
Figure 3 Immunohistochemical staining for DARPP. (A) Oesophageal
gland cells, (B) gangliocytes stained as an internal control. (C) DARPP
expression is not detected in normal oesophageal mucous membrane. (D)
Almost all the cancer cell membrane and cytoplasm were stained for
DARPP. (E) DARPP immunoreactivity was not observed in cancer cells,
while gland cells showed strong staining as an internal control. (F) DARPP
immunoreactivity was not observed in dysplastic cells, while cancer cells
showed staining. (original magnifications: A, B,  400; C,  40; D, E,
 100; F,  40).
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were two types of OSCC cell lines, DARPP-expressing and -
nonexpressing cells.
The RT–PCR results appear to accurately reflect the
status of DARPP expression. Although both DARPP isoforms
were frequently overexpressed in gastric cancer, 30% of
OSCC samples expressed DARPP-32 alone. Based on our
RT–PCR and Western blot data, we believe that DARPP
immunoreactivity in OSCC specimens is specific to DARPP-32
but not t-DARPP.
In TE2 and TE13 cell lines, manual sequencing analyses were
performed, but no genetic alterations of DARPP-32 were found
(figure not shown). Therefore, the difference in DARPP-32
expression is not likely to be caused by mutation.
Several reports have described the pattern of progression from
normal mucous to dysplasia, to carcinoma in situ (Shi et al, 1999;
Saeki et al, 2002; Shirai et al, 2002). Oesophageal dysplasia is also
believed to be one of the precursors for OSCC. The ratio of DARPP
immunopositivity in dysplasia was significantly lower (Po0.0001;
w
2 test) compared to that in tumour. These data suggest that
overexpression of DARPP arises at the late phase of neoplastic
progression of the oesophagus. Moreover, these features could
be an advantage to distinguish between cancer and dysplasia
in diagnosis of biopsy specimens (30.3% sensitivity, 97.8%
specificity).
It remains unclear whether DARPP-32 is an oncogene like ras,
myc and src because some normal tissue expresses DARPP-32.
Overexpression of DARPP-32, however, is related to carcinogen-
esis in 30% of OSCC. Moreover, DARPP-32-positive tumours
appear to have a less aggressive character than DARPP-32
negative tumours. This characteristic is not due to exclusion by
the host immune response. We previously reported that the
cooperative role of CD4
þ and CD8
þ T cells appears to drastically
improve the prognosis of patients with OSCC (Cho et al, 2003).
Despite the better prognosis in patients with DARPP-32-positive
tumours, the expression of DARPP-32 in OSCC was not
correlated with infiltration of CD4
þ and/or CD8
þ T cells
(P¼0.7409; w
2 test).
DARPP-32 is a known protein that acts as a PP1 inhibitor or an
MAPK, CREB mediator. Protein phosphatase 1 and other protein
phosphatases that reverse the action of cyclin-dependent kinases
are emerging as important cell cycle regulatory enzymes
(Oliver and Shenolikar, 1998; Schonthal, 2001; Wang et al, 2001).
Many oncogenes have been shown to encode proteins that
trasmit mitogenic signals upstream of the MAPK pathway
(Seger and Krebs, 1995; Sebolt-Leopold, 2000). Phosphorylation
of CREB generates signals that inhibit apotosis (Jean et al, 1998;
Jean and Bar-Eli, 2000). Control of phosphorylation in
gastrointestinal malignancies has recently been reported as an
important mechanism for some neoplasia (Saha et al, 2001;
Higashi et al, 2002). To understand the potential role of
DARPP-32 in human OSCC, however, additional studies and
biological assays are required. We are now proceeding with further
investigation to clarify the biological function of DARPP-32 in
OSCC cells.
We conclude that DARPP-32 expression arises after a phase of
dysplasia in OSCC. Moreover, DARPP-32-positive tumours have a
less aggressive character than those that are not.
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Table 1 Relationship between clinicopathologic features and DARPP-32
expression in surgical specimens of oesophageal squamous cell carcinoma
Variables
DARPP-32
positive (n¼37)
DARPP-32
negative (n¼85) P value
a
Gender
Male 32 73 0.9294
Female 5 12
Age
X65 11 38 0.1209
o65 26 47
p-Stage
I, II 29 49 0.0284
III, IV 8 36
Grade
G1 11 20 0.4696
Others 26 65
p-T classification
T1, T2 26 43 0.0438
T3, T4 11 42
p-N classification
N0 24 37 0.0303
N1 13 48
p-M classification
M0 31 72 0.8973
M1 6 13
Tumour size
X4.5cm 13 51 0.0115
o4.5cm 24 34
Surgical margin
Positive 2 6 0.7345
Negative 35 79
Adjuvant therapy
Yes 17 33 0.4622
No 20 52
aThe P-value was calculated by chi-square test.
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Figure 4 Comparison of overall survival curves for patients with
DARPP-32-positive and -negative tumors out of 122 patients who
underwent radical oesophagectomy.
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